Hepatology International is a peer-reviewed journal featuring articles written by clinicians, clinical researchers and basic scientists is dedicated to research and patient care issues in hepatology. This journal focuses mainly on new and emerging diagnostic and treatment options, protocols and molecular and cellular basis of disease pathogenesis, new technologies, in liver and biliary sciences.
Hepatology International publishes original research articles related to clinical care and basic research; review articles; consensus guidelines for diagnosis and treatment; invited editorials, and controversies in contemporary issues. The journal does not publish case reports..
Hepatology International requests that all authors comply to Springer’s ethical policies. These ethical statements should be clearly indicated on all articles for all 3 ethics statements and for all authors mentioned by name. These statements should be placed at the end of each article just before the Reference section.
To visit our ethics statements please visit the following links:
Conflict of Interest and Ethical Standards: http://www.springer.com/authors?SGWID=0-111-6-791531-0
Informed Consent: http://www.springer.com/authors?SGWID=0-111-6-608209-0
Statement of Human and Animal Rights: http://www.springer.com/authors?SGWID=0-111-6-608309-0
Hepatology International is the official journal of the Asian Pacific Association for the Study of the Liver (APASL).
Now indexed by ISI
Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd–Chiari syndrome on warfarin
To view the rest of this content please follow the download PDF link above.